Vernal keratoconjunctivitis (VKC) is a rare form of chronic allergic inflammatory disorder that affects the cornea and conjunctiva of the eye and is normally associated with secondary form of keratopathy. Symptom of vernal keratoconjunctivitis involves development of giant papillae, typically in a perosn’s upper tarsal conjunctiva. In certain rare cases, it may develop in the corneoscleral limbus in the conjunctiva. The disease has a seasonal recurrence and normally affects children and adolescents. It predominantly affects boys in the age group of 5 to 25 years and is seen to subside at the onset of puberty; however, cases of VKC have also been reported among septuagenarian patients. Vernal keratoconjunctivitis frequently occurs in arid and warmer climates and is commonly observed in the Mediterranean area, Japan, Central Africa, South America, and India.

A primary factor driving the growth of the vernal keratoconjunctivitis treatment market is the rising incidence of vernal keratoconjunctivitis and other allergic eye disorders observed across the globe. While vernal keratoconjunctivitis has a low prevalence rate in regions having cold climates such as North America and Northern Europe (of around 1 in 5000 eye disease cases), it has a relatively high frequency in other parts of the world with warm and arid climates. In tropical regions, such as India and Sub-Saharan Africa, VKC accounts for 3% of serious ophthalmic diseases. Rising prevalence of the disease in these regions, coupled with its seasonal recurring nature, is expected to drive the growth of the vernal keratoconjunctivitis treatment market during the forecast period. Additionally, continued focus of pharmaceutical companies on developing new and improved medication for the treatment of vernal keratoconjunctivitis is also expected to boost the growth of the market. For instance, in July 2017, Santen SAS announced that it had received the positive opinion from the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP), recommending the marketing authorization (MAA) for ciclosporin (Verkazia), 1mg/mL eye drop to be used in case of severe vernal keratoconjunctivitis in pediatric population. The eye drops were developed using the company’s Novasorb proprietary technology that helps in improving the delivery of ciclosporin into the eye and reduces symptoms of the disease and improves ocular surface damage. Allakos, Inc., a privately-held clinical stage company initiated phase 1 clinical trials for AK002, which is a non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody targeted against Siglec-8, an inhibitory receptor selectively expressed on mast cells and eosinophils in patients with vernal keratoconjunctivitis. However, strict regulatory conditions and uncertain reimbursement scenario are anticipated to hamper the growth of the vernal keratoconjunctivitis treatment market during the forecast period.

The vernal keratoconjunctivitis treatment market can be segmented based on drug type, end-user, and geography. In terms of drug type, the market can be divided into cromolyn sodium, lodoxamide, ciclosporin, emedastine, and others. Based on end-user, the market can be classified into hospitals, ambulatory surgical centers, and ophthalmic clinics. 

Geographically, the global vernal keratoconjunctivitis treatment market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominates the global market due to growing incidence of ocular eye disorders in the region. Asia Pacific is followed by Europe and Middle East & Africa. The vernal keratoconjunctivitis treatment market in Europe is anticipated to register a healthy growth rate during the forecast period due to launch of new products by pharmaceutical companies for the treatment of the disease.

Prominent players operating in the global vernal keratoconjunctivitis treatment market are Akorn, Inc, Alcon, Allakos, Inc., Allergan, Inc, and Santen SAS.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Vernal Keratoconjunctivitis Treatment Market

Pre Book